Swiss National Bank Buys 2,700 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Swiss National Bank increased its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 0.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 289,300 shares of the biopharmaceutical company’s stock after buying an additional 2,700 shares during the quarter. Swiss National Bank owned 0.19% of TG Therapeutics worth $8,708,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Victory Capital Management Inc. increased its position in TG Therapeutics by 24.7% during the 3rd quarter. Victory Capital Management Inc. now owns 32,679 shares of the biopharmaceutical company’s stock valued at $764,000 after purchasing an additional 6,467 shares during the period. KBC Group NV lifted its holdings in shares of TG Therapeutics by 30.5% in the 3rd quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,092 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of TG Therapeutics by 3.1% in the 3rd quarter. Empowered Funds LLC now owns 46,431 shares of the biopharmaceutical company’s stock worth $1,086,000 after purchasing an additional 1,386 shares in the last quarter. Mutual of America Capital Management LLC bought a new position in shares of TG Therapeutics in the 3rd quarter worth $469,000. Finally, Thrivent Financial for Lutherans bought a new position in shares of TG Therapeutics in the 3rd quarter worth $2,450,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Up 2.6 %

Shares of TGTX opened at $42.99 on Friday. The firm has a market cap of $6.75 billion, a P/E ratio of -429.86 and a beta of 2.30. The stock has a 50 day simple moving average of $33.17 and a two-hundred day simple moving average of $29.63. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a 1 year low of $12.93 and a 1 year high of $43.15.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. On average, analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on TGTX shares. JPMorgan Chase & Co. raised their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $40.67.

Insider Buying and Selling

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.50% of the stock is currently owned by insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.